Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609994 · ClinicalTrials.gov registry record · Phase 1
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
A Phase 1 study of Low Grade Glioma of Brain, sponsored by Katy Peters, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05609994: Recruiting Phase 1 study of Low Grade Glioma of Brain, sponsored by Katy Peters, MD, PhD.
NCT05609994 is a Phase 1 study of Low Grade Glioma of Brain that is actively recruiting participants, run by Katy Peters, MD, PhD. The registered enrollment target is 48 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05609994, a Phase 1 study of Low Grade Glioma of Brain, is actively recruiting participants, sponsored by Katy Peters, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
Primary Outcome
The proportion of patients with an unacceptable toxicity
Conditions Studied
Interventions
- DRUG PEPIDH1M vaccine + vorasidenib
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-07-15 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
What NCT05609994 shows while recruiting
NCT05609994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Low Grade Glioma of Brain appearing as the primary indexed condition, and to 1 intervention - of which PEPIDH1M vaccine + vorasidenib is the first listed.
NCT05609994 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05609994 about?
NCT05609994 is a clinical study titled "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas". The purpose of this study is to determine the safety and efficacy of a PEPIDH1M vaccine in combination with vorasidenib, a dual inhibitor of mutant IDH1 and IDH2 enzymes, in adult patients diagnosed with recurrent IDH1 mutant lower grade gliomas.
What is the current status of trial NCT05609994?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-07-15. Estimated completion is 2029-08.
What conditions does trial NCT05609994 study?
This clinical trial studies the following conditions: Low Grade Glioma of Brain.
What interventions are being tested in trial NCT05609994?
The interventions under investigation include: PEPIDH1M vaccine + vorasidenib (DRUG).
Who is sponsoring clinical trial NCT05609994?
This trial is sponsored by Katy Peters, MD, PhD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05609994 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low Grade Glioma of Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05609994's enrollment target sits among peer trials
48 1026th of 2000 higher than 948 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI